No Data
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Express News | J&J: Rybrevant Plus Lazcluze Shows Statistically Significant & Clinically Meaningful Improvement in Overall Survival Vs Osimertinib
Express News | J&J: Median Overall Survival Improvement With Rybrevant Plus Lazcluze Expected to Exceed One Year
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
Stock Of The Day: Will Johnson & Johnson Take The Market Lower?
loading...